Stem cell technology using bioceramics: hard tissue regeneration towards clinical application

Mesenchymal stem cells (MSCs) are adult stem cells which show differentiation capabilities toward various cell lineages. We have already used MSCs for treatments of osteoarthritis, bone necrosis and bone tumor. For this purpose, culture expanded MSCs were combined with various ceramics and then impl...

Full description

Bibliographic Details
Main Author: Hiroe Ohnishi, Yasuaki Oda and Hajime Ohgushi
Format: Article
Language:English
Published: Taylor & Francis Group 2010-01-01
Series:Science and Technology of Advanced Materials
Online Access:http://iopscience.iop.org/1468-6996/11/1/014110
id doaj-f09561c99a4e47bf9aa09c499afbf3a8
record_format Article
spelling doaj-f09561c99a4e47bf9aa09c499afbf3a82020-11-24T23:34:36ZengTaylor & Francis GroupScience and Technology of Advanced Materials1468-69961878-55142010-01-01111014110Stem cell technology using bioceramics: hard tissue regeneration towards clinical application Hiroe Ohnishi, Yasuaki Oda and Hajime OhgushiMesenchymal stem cells (MSCs) are adult stem cells which show differentiation capabilities toward various cell lineages. We have already used MSCs for treatments of osteoarthritis, bone necrosis and bone tumor. For this purpose, culture expanded MSCs were combined with various ceramics and then implanted. Because of rejection response to allogeneic MSC implantation, we have utilized patients' own MSCs for the treatment. Bone marrow is a good cell source of MSCs, although the MSCs also exist in adipose tissue. When comparing osteogenic differentiation of these MSCs, bone marrow MSCs show more extensive bone forming capability than adipose MSCs. Thus, the bone marrow MSCs are useful for bone tissue regeneration. However, the MSCs show limited proliferation and differentiation capabilities that hindered clinical applications in some cases. Recent advances reveal that transduction of plural transcription factors into human adult cells results in generation of new type of stem cells called induced pluripotent stem cells (iPS cells). A drawback of the iPS cells for clinical applications is tumor formation after their in vivo implantation; therefore it is difficult to use iPS cells for the treatment. To circumvent the problem, we transduced a single factor of either SOX2 or NANOG into the MSCs and found high proliferation as well as osteogenic differentiation capabilities of the MSCs. The stem cells could be combined with bioceramics for clinical applications. Here, we summarize our recent technologies using adult stem cells in viewpoints of bone tissue regeneration.http://iopscience.iop.org/1468-6996/11/1/014110
collection DOAJ
language English
format Article
sources DOAJ
author Hiroe Ohnishi, Yasuaki Oda and Hajime Ohgushi
spellingShingle Hiroe Ohnishi, Yasuaki Oda and Hajime Ohgushi
Stem cell technology using bioceramics: hard tissue regeneration towards clinical application
Science and Technology of Advanced Materials
author_facet Hiroe Ohnishi, Yasuaki Oda and Hajime Ohgushi
author_sort Hiroe Ohnishi, Yasuaki Oda and Hajime Ohgushi
title Stem cell technology using bioceramics: hard tissue regeneration towards clinical application
title_short Stem cell technology using bioceramics: hard tissue regeneration towards clinical application
title_full Stem cell technology using bioceramics: hard tissue regeneration towards clinical application
title_fullStr Stem cell technology using bioceramics: hard tissue regeneration towards clinical application
title_full_unstemmed Stem cell technology using bioceramics: hard tissue regeneration towards clinical application
title_sort stem cell technology using bioceramics: hard tissue regeneration towards clinical application
publisher Taylor & Francis Group
series Science and Technology of Advanced Materials
issn 1468-6996
1878-5514
publishDate 2010-01-01
description Mesenchymal stem cells (MSCs) are adult stem cells which show differentiation capabilities toward various cell lineages. We have already used MSCs for treatments of osteoarthritis, bone necrosis and bone tumor. For this purpose, culture expanded MSCs were combined with various ceramics and then implanted. Because of rejection response to allogeneic MSC implantation, we have utilized patients' own MSCs for the treatment. Bone marrow is a good cell source of MSCs, although the MSCs also exist in adipose tissue. When comparing osteogenic differentiation of these MSCs, bone marrow MSCs show more extensive bone forming capability than adipose MSCs. Thus, the bone marrow MSCs are useful for bone tissue regeneration. However, the MSCs show limited proliferation and differentiation capabilities that hindered clinical applications in some cases. Recent advances reveal that transduction of plural transcription factors into human adult cells results in generation of new type of stem cells called induced pluripotent stem cells (iPS cells). A drawback of the iPS cells for clinical applications is tumor formation after their in vivo implantation; therefore it is difficult to use iPS cells for the treatment. To circumvent the problem, we transduced a single factor of either SOX2 or NANOG into the MSCs and found high proliferation as well as osteogenic differentiation capabilities of the MSCs. The stem cells could be combined with bioceramics for clinical applications. Here, we summarize our recent technologies using adult stem cells in viewpoints of bone tissue regeneration.
url http://iopscience.iop.org/1468-6996/11/1/014110
work_keys_str_mv AT hiroeohnishiyasuakiodaandhajimeohgushi stemcelltechnologyusingbioceramicshardtissueregenerationtowardsclinicalapplication
_version_ 1725528552246345728